Sarepta Therapeutics's total assets for Q3 2025 were $3.49B, a decrease of -5.06% from the previous quarter. SRPT total liabilities were $2.17B for the fiscal quarter, a -6.42% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.